HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
BASEL, Switzerland and CAMBRIDGE, Mass., April 27, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at the InterContinental Boston Hotel in Boston, MA.
Event: 42nd Annual Deutsche Bank Health Care Conference
Date: Wednesday, May 3rd
Time: 4:10 PM EDT
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
